Somatoform Disorders Clinical Trial
Official title:
Treatment of Multi-organ Bodily Distress Syndrome. A Double-blinded Placebo Controlled Trial of the Effects of Imipramine (Stress-3)
The aim of this study is to test the effect of the tricyclic antidepressant Imipramine in patients with longlasting health problems with no known medical explanation, defined as multi-organ Bodily distress syndrome (BDS). Pharmacological treatment of patients with BDS have never been tested, and Imipramine i low dosage (10-75 mg) has the potential of reducing both pain and other symptoms of bodily distress for patients with BDS. Control conditions are pill placebo. Study duration is 19 weeks for each of the 140 patients. End point is 13 weeks, i.e. after 10 weeks of 25-75 mg study drug.
The aim of this study is to test the effect of Imipramine in patients with multi-organ Bodily distress syndrome (BDS). BDS is a unifying diagnosis that encompasses a group of closely related conditions such as somatization disorder, fibromyalgia, irritable bowel syndrome and chronic fatigue syndrome. The project consists of a double-blinded placebo controlled trial of treatment with the tricyclic antidepressant Imipramine in dosages of 25-75 mg. Primary outcome is patient-rated improvement measured by Clinical Global Improvement Scale (CGI-I). Secondary outcome is functional level (physical, mental and social) measured by the SF-36 Physical Component Summary (PCS). The study requires 140 participants and study duration is 19 weeks for each patient. End point is 13 weeks, i.e. after 10 weeks of 25-75 mg study drug. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00276887 -
Cognitive Behavior Therapy for Somatization Disorder
|
Phase 2 | |
| Enrolling by invitation |
NCT05565352 -
Observation of Ketamine Treatment Safety and Tolerability in Adult Psychiatry Clinic Medical University of Gdańsk Inpatients
|
||
| Active, not recruiting |
NCT04847310 -
Cost-benefit Evaluation of a Transdiagnostic Psychological Treatment for Emotional Disorders in Primary Care
|
N/A | |
| Completed |
NCT05631860 -
Psychological Risk Factors for Functional Somatic Disorders
|
||
| Completed |
NCT05611606 -
Welfare Benefits in Functional Somatic Disorders
|
||
| Completed |
NCT02151500 -
Stress and Health Interview for Primary Care Patients With Medically Unexplained Symptoms
|
N/A | |
| Completed |
NCT01590992 -
Treatment of Globus Sensations With Psychotherapy
|
N/A | |
| Completed |
NCT00368212 -
Integrated Treatment Program for Hypochondriasis in Primary Care Settings
|
Phase 3 | |
| Completed |
NCT00149799 -
Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
|
Phase 3 | |
| Terminated |
NCT02843932 -
Subjective Perception of Motor Control During Psychogenic Disorders
|
N/A | |
| Terminated |
NCT03904784 -
School Withdrawal in Adolescents
|
||
| Recruiting |
NCT04807933 -
Neurovegetative Decoupling in Somatoform Disorders : Biofeedback Interest
|
N/A | |
| Completed |
NCT01119469 -
Comparing Cognitive Therapy and Exposure Therapy in Individuals With Hypochondriasis
|
Phase 3 | |
| Recruiting |
NCT03188861 -
Systematic Screening for Comorbid Psychological Conditions in Cardiac ACSC Patients With Multimorbidity in the ED
|
||
| Recruiting |
NCT04835103 -
Build a Research Clinic for Somatoform Patients
|
N/A | |
| Completed |
NCT02346071 -
Acceptance and Commitment Group Therapy for Adolescents With a Range of Functional Somatic Syndromes
|
N/A | |
| Completed |
NCT01518647 -
Acceptance and Commitment Therapy for Patients With Multi-organ Bodily Distress Syndrome (Stress-4)
|
N/A | |
| Recruiting |
NCT01391897 -
Epigenetics of Posttraumatic Stress Disorder and Somatoform Disorders in the Course of Psychotherapy
|
N/A | |
| Completed |
NCT01924715 -
Evaluating the Cost Effectiveness of ISTDP: A Quasi Experimental Study
|
N/A | |
| Completed |
NCT00130988 -
DEPENAS: A Psychosocial Intervention for Patients With Medically Unexplained Symptoms
|
Phase 3 |